Dr. Boxer received his MD and PhD from the New York University Medical Center Medical Scientist Training Program, completed a Neurology Residency at Stanford and a Neurobehavior Fellowship at UCSF. He is the Principal Investigator of the Alzheimer’s Disease Tau Platform clinical trial. He is co-Principal Investigator of the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) project and the FTD Prevention Initiative (FPI). He is PI of the Neurofilament Surveillance Project (NSP) and also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI). He is organizing PI for Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD), a novel biomarker study working to understand the etiologies of early onset dementia in Black/African American and Latino/a/x individuals. He is the lead PI of the planned NIH Alzheimer’s Clinical Trial Consortium’s (ACTC) Tau Platform clinical trial (ATP) as well as a planned PSP Platform Trial. He co-chaired the National Alzheimer’s Project Act (NAPA) FTLD Research Recommendations Committee in 2019 and 2022. He was founding co-chair of the FTLD Research Roundtable and co-chairs the PSP Research Roundtable, academic-industry collaborative groups working to speed the development of new therapies for FTLD, CBD and PSP.
.png)
